% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • weightbayou weightbayou Mar 9, 2013 8:57 PM Flag

    One of the major 4th quarter highlights

    Completed enrollment in the Phase 1 portion of the CDX-1127 solid tumor arm. CDX-1127 was determined to be well-tolerated to date, including at the highest dose level. Celldex continues to enroll patients in the dose escalation portion of the lymphoma and leukemia arm.

    Sentiment: Strong Buy

3.83+0.11(+2.96%)Sep 23 4:00 PMEDT